A/Prof. Liu Haiyan
Department of Microbiology and Immunology, Yong Loo Ling School of Medicine
Immune regulation in the cancer microenvironment and immunotherapy.
We are interested in elucidating the regulatory roles of the inflammatory cytokines and the interactions among immune cell subsets, tumor cells and tissue residential cells. We are also interested in combining specific cancer vaccine, oncolytic virus, cytokine treatment and inhibitory checkpoint blockade to further boost the efficacy of tumor immunotherapy.
The regulatory mechanisms in the cancer microenvironment can significantly affect the outcomes of current immunotherapy. Combining with environment-modulating therapy is the future direction for enhancing efficacy of cancer immunotherapy.
Identifying novel therapeutic targets and combinational strategies for cancer immunotherapy.
Our laboratory has some unique murine tumor models, including hepatocellular carcinoma. We are also experts in analysing immune cell subsets and their activation status in various organs.
1. Liu Y, Song Y, Lin D, Lei L, Mei Y, Jin Z, Gong H, Zhu Y, Hu B, Zhang Y, Zhao Y, Teo HY, Qiu J, Jiang W, Dong C, Wu D, Huang Y, Liu H (2019) NCR– group 3 innate lymphoid cells orchestrate IL-23/IL-17 axis to promote hepatocellular carcinoma development. EBioMedicine 41:333-344.
2. Jin Z, Lei L, Lin D, Liu Y, Song Y, Gong H, Zhu Y, Mei Y, Hu B, Wu Y, Zhang G, Liu H (2018) IL-33 released in the liver inhibits tumor growth via promoting CD4+ and CD8+ T cell responses in hepatocellular carcinoma. Journal of Immunology 201(12):3770-3779
3. Song Y, Hu B, Liu Y, Jin Z, Zhang Y, Lin D, Zhu Y, Lei L, Gong H, Mei Y, Teo HY, Wu D, Liu H (2018) IL-12/IL-18-preactivated donor NK cells enhance graft-versus-leukemia effects and mitigate graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. European Journal of Immunology 48(4):670-682.
4. Cai Y, Ma S, Liu Y, Gong H, Cheng Q, Hu B, Wu Y, Yu X, Dong C, Sun K, Wu D, Liu H (2018) Adoptively transferred donor IL-17-producing CD4+ T cells augment, but IL-17 alleviates, acute graft-versus-host disease. Cellular and Molecular Immunology 15(3):233-245.
5. Gong H, Ma S, Liu S, Liu Y, Jin Z, Zhu Y, Song Y, Lei L, Hu B, Mei Y, Liu H, Liu Y, Wu Y, Dong C, Xu Y, Wu D, Liu H (2018) IL-17C mitigates murine acute graft-versus-host disease by promoting intestinal barrier functions and Treg differentiation. Frontier in Immunology 9:2724